Oslo, Norway – PCI Biotech (OSE: PCIB) has announced the start of an evaluation process to consider a structured wind-up of the company. This follows the decision to discontinue all research and development activities, as previously communicated on 8 January 2026.
The company is continuing to explore strategic alternatives while assessing the best approach to manage its remaining operations and obligations.
**Why this matters**
The evaluation marks a significant step in PCI Biotech’s transition after halting R&D efforts. The outcome will impact stakeholders, including investors and employees, as the company determines its future direction.